About Hema.to
Hema.to is a company based in Munchen (Germany) founded in 2019. Hema.to has raised $7.7 million across 2 funding rounds from investors including LUMO Labs, Bayern Kapital and Elaia. Hema.to offers products and services including hema.to BASE and hema.to B-NHL. Hema.to operates in a competitive market with competitors including PathAI, Deepcell, Aignostics, Pictor Labs and Neko Health, among others.
- Headquarter Munchen, Germany
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Hema.To Gmbh
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$7.7 M (USD)
in 2 rounds
-
Latest Funding Round
$3.78 M (USD), Seed
Feb 27, 2025
-
Investors
LUMO Labs
& 4 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Hema.to
Hema.to offers a comprehensive portfolio of products and services, including hema.to BASE and hema.to B-NHL.
Automates single cell classification in cytometry for clinical diagnostics
Offers AI-based recommendations for B-NHL blood cancer diagnosis
People of Hema.to
Unlock access to complete
Funding Insights of Hema.to
Hema.to has successfully raised a total of $7.7M across 2 strategic funding rounds. The most recent funding activity was a Seed round of $3.78 million completed in February 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Hema.to
Hema.to has secured backing from 5 investors, including venture fund investors. Prominent investors backing the company include LUMO Labs, Bayern Kapital and Elaia.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Opportunities are created for impact-driven ventures in emerging technologies.
|
Locked | Locked | Locked | |
|
High-tech industries are targeted for investments by Bayern Kapital.
|
Locked | Locked | Locked | |
|
Venture capital firm focused on early-stage investments
|
Locked | Locked | Locked |
Investor details for Hema.to
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Hema.to
Investment portfolio details for Hema.to
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Hema.to
Detailed financials for Hema.to
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Hema.To Comparisons
Peer comparison for Hema.to
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Hema.to
Hema.to operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as PathAI, Deepcell, Aignostics, Pictor Labs and Neko Health, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Provider of AI-based solutions for clinical diagnosis of cancer and other diseases
|
|
| Locked | Locked | Locked |
AI-powered single cell classification and isolation technology for clinical research
|
|
| Locked | Locked | Locked |
AI-based pathology diagnostic software is provided for medical analysis.
|
|
| Locked | Locked | Locked |
AI-based tools for pathological image analysis are provided to labs.
|
|
| Locked | Locked | Locked |
Platform offering solutions for preventive health scans
|
|
| Locked | Locked | Locked |
Imaging systems and AI software for microscopes are developed.
|
Detailed competitors of Hema.to
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Hema.To
Complete news archive for Hema.to
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Hema.to
Hema.to was founded in 2019 and raised its 1st funding round 4 years after it was founded.
Hema.to is headquartered in Munchen, Germany. It is registered at Munchen, Bayern, Germany.
Hema.to is a funded company, having raised a total of $7.7M across 2 funding rounds to date.
Hema.to was founded in 2019 and is headquartered in Munich, Germany. Operations focus on the health technology sector, where SaaS platforms integrated with artificial intelligence are utilized for leukemia diagnostics. Services include software tools that assist in analyzing blood samples and identifying leukemia indicators. The company serves medical professionals through cloud-based solutions, emphasizing accuracy in diagnostic processes across European markets.
Hema.to's top competitors include Aignostics, Pictor Labs and PathAI.
Hema.to offers hema.to BASE and hema.to B-NHL.
Hema.to has 5 investors. Key investors include LUMO Labs, Bayern Kapital, Elaia, Heal Capital, and High-Tech Gründerfonds.